Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

被引:11
|
作者
Quan, Hongzhi [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Sixuan [1 ,2 ,3 ,4 ,5 ,6 ]
Shan, Zhongyan [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Ziyi [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Tianjun [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Yanjia [1 ,2 ,3 ,4 ,5 ,6 ]
Yao, Zhigang [1 ,2 ,3 ,4 ,6 ,7 ]
Fang, Liangjuan [8 ,9 ]
机构
[1] Cent South Univ, Hunan Key Lab Oral Hlth Res, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Hunan 3D Printing Engn Res Ctr Oral Care, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Hunan Clin Res Ctr Oral Major Dis & Oral Hlth, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Dept Oral Maxillofacial Surg, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha 410008, Hunan, Peoples R China
[8] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[9] Cent South Univ, Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
基金
中国博士后科学基金;
关键词
Oral squamous cell carcinoma; Oral submucous fibrosis; Programmed death ligand-1; Programmed death 1; Prognosis; PD-L1; EXPRESSION; CANCER; MICROENVIRONMENT; BLOCKADE; GRADE;
D O I
10.1016/j.archoralbio.2020.104916
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. Methods: PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. Results: The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). Conclusions: The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers
    Zhou, Rong-Miao
    Li, Yan
    Liu, Jiang-Hui
    Wang, Na
    Huang, Xi
    Cao, Shi-Ru
    Shan, Bao-En
    CANCER BIOMARKERS, 2018, 21 (01) : 65 - 71
  • [32] Dynamic contrast-enhanced MRI as a predictor of programmed death ligand-1 expression in patients with oral squamous cell carcinoma
    Tekiki, Nouha
    Fujita, Mariko
    Okui, Tatsuo
    Kawai, Hotaka
    Oo, May
    Kawazu, Toshiyuki
    Hisatomi, Miki
    Okada, Shunsuke
    Takeshita, Yohei
    Barham, Majd
    Nagatsuka, Hitoshi
    Yanagi, Yoshinobu
    Asaumi, Jun-Ichi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [33] Commentary on "Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma"
    Pena-Cardelles, Juan Francisco
    Moro-Rodriguez, Jose Ernesto
    Cebrian-Carretero, Jose Luis
    Pozo-Kreilinger, Jose Juan
    OPEN MEDICINE, 2022, 17 (01): : 227 - 228
  • [34] Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
    Mudassar, Faiqa
    Shen, Han
    Cook, Kristina M.
    Hau, Eric
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2022, 66 (04) : 560 - 574
  • [35] Programmed Cell Death-1 and Programmed Cell Death Ligand-1 in Childhood Acute B-Lymphoblastic Leukemia: Expression and Significance as Biomarker
    Allam, Ahmed Ahmed
    Ahmed, Heba A.
    Hassan, Mohammad Ahmad
    Khaled, Safaa A. A.
    Shibl, Azza
    Osman, Amira Mahmoud
    Ali, Nada Mohamed Rafat
    Ahmed, Nesma Mokhtar
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2025,
  • [36] Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kondo, Tsunenori
    Shinohara, Nobuo
    Nonomura, Norio
    Ozono, Seiichiro
    Eto, Masatoshi
    Tatsugami, Katsunori
    Takayama, Tatsuya
    Matsuyama, Hideyasu
    Kishida, Takeshi
    Oya, Mototsugu
    CANCER SCIENCE, 2019, 110 (06) : 1820 - 1828
  • [37] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
    Zhang, Ying
    Zhu, Weipei
    Zhang, Xueguang
    Qu, Qiuxia
    Zhang, Liyuan
    ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
  • [38] Programmed cell death ligand-1 expression in gastroentero-pancreatic neuroendocrine tumors
    Oktay, Esin
    Yalcin, Gizem Donmez
    Ekmekci, Sumeyye
    Kahraman, Dudu Solakoglu
    Yalcin, Abdullah
    Degirmenci, Mustafa
    Dirican, Ahmet
    Altin, Zeynep
    Ozdemir, Ozlem
    Surmeli, Zeki
    Diniz, Gulden
    Ayhan, Semin
    Bulut, Gulcan
    Erdogan, Atike
    Uslu, Ruchan
    JOURNAL OF BUON, 2019, 24 (02): : 779 - 790
  • [39] Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
    Zhang, Chen
    Yang, Qing
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [40] Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials
    Huang, Zilu
    Zheng, Shuohan
    Ding, Shirong
    Wei, Yinghong
    Chen, Chen
    Liu, Xing
    Li, He
    Xia, Yunfei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 676 - 687